HPLC vs Mass Spec: What Peptide Purity Really Means

A certificate of analysis for a research peptide will almost always carry two headline claims: a purity percentage and a confirmed molecular weight. They are frequently read as a single statement of quality, yet they come from two different analytical techniques that answer two different questions. High-performance liquid chromatography (HPLC) asks how much of the material behaves like a single species. Mass spectrometry (MS) asks what that species actually is. A batch can satisfy one test and fail the other, which is why a laboratory needs both to judge whether a lot is fit for its purpose. This article explains what each method measures, where each one is blind, and what a purity figure does and does not tell a researcher.

What HPLC Actually Measures

Peptide purity is almost always determined by reversed-phase HPLC (RP-HPLC). The sample is dissolved and passed through a column packed with hydrophobic silica, most commonly a C18 stationary phase, using a gradient of water and acetonitrile with an ion-pairing acid such as trifluoroacetic acid (TFA). Components elute at different times according to their hydrophobicity, and a detector records the signal as a chromatogram, a trace of peaks against time.

For peptides the detector is normally an ultraviolet (UV) absorbance monitor set between roughly 210 and 220 nm. Suppliers of synthetic peptides describe 215 nm as well suited to this work because it targets absorbance by the peptide bond itself, so that essentially every peptide-related species in the sample is detected regardless of its side-chain composition (Alta Bioscience technical documentation; Bachem quality-control guidance). Purity is then calculated as the area of the main peak divided by the total area of all integrated peaks, expressed as a percentage.

That calculation carries several assumptions worth making explicit. It is a relative measure: a figure of 98% means that 98% of the integrated UV signal belongs to the main peak, not that 98% of the powder is peptide. It depends on the integration parameters chosen by the analyst, including the baseline, the threshold for what counts as a peak, and the gradient used. And it can only resolve what the column separates. Impurities that co-elute with the main peak, or that lack UV absorbance at the monitored wavelength, are invisible to the calculation.

What Mass Spectrometry Adds

Mass spectrometry determines the mass-to-charge ratio of ionised molecules. For synthetic peptides the two common configurations are matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) and electrospray ionisation (ESI), the latter frequently coupled directly to an HPLC system as LC-MS. Either approach yields a measured molecular weight that can be compared with the theoretical mass calculated from the intended sequence.

This is an identity test. If the measured mass matches the expected mass within the instrument’s tolerance, the dominant species is consistent with the target structure. If it does not, the sample may contain a deletion sequence, a truncation, an incompletely deprotected product, or an entirely different molecule. HPLC alone cannot distinguish these cases, because a clean, single-peak chromatogram tells the analyst only that one species is present, not which one. Documentation from peptide manufacturers is consistent on this division of labour: MS confirms that the intended product was made, while HPLC estimates how much of the sample it represents.

Mass spectrometry has its own limits. It is not inherently quantitative in the way a calibrated assay is, since ionisation efficiency differs between species, and it does not by itself report how much peptide is in the vial. It also confirms mass rather than sequence; two isomeric peptides with the same composition can share a mass. For that reason, tandem MS (MS/MS) fragmentation is used when sequence confirmation is required.

Why Purity Is Not the Same as Peptide Content

The most common misunderstanding of a purity figure is the assumption that it describes the entire contents of the vial. A lyophilised peptide powder contains the peptide, but also water and counterions. Peptides carry basic groups, including the free N-terminus and the side chains of arginine, lysine, and histidine, and these are bound as salts to the acid used during purification, typically TFA or acetate. Bachem’s technical guidance notes that such counterions are firmly associated with the peptide and cannot be completely removed. Hydrophilic peptides additionally absorb moisture, even after careful lyophilisation.

The fraction of the powder that is genuinely peptide is called the net peptide content (NPC), defined as the percentage of peptide relative to non-peptidic material, mostly counterions and moisture. LifeTein and other peptide manufacturers state explicitly that net peptide content is different from peptide purity, and that it can vary between batches depending on purification and lyophilisation conditions. A sample can therefore be 98% pure by HPLC while the powder itself contains substantially less than 98% peptide by weight.

Determining net content requires a different technique. Amino acid analysis (AAA) hydrolyses the peptide in strong acid, separates and quantifies the constituent amino acids chromatographically, and back-calculates how much peptide was present; it provides no sequence information, but it does report quantity. Karl Fischer titration is used to measure water content directly. Without one of these measurements, neither HPLC nor MS can tell a researcher how much peptide a stated mass of powder truly contains, which matters for any experiment in which molar concentration is important.

Reading the Numbers Together

Because the methods are complementary, a meaningful quality package presents them together, and ideally as raw data rather than a summary line. A researcher reviewing analytical documentation can ask a short series of questions.

Is the chromatogram shown, and does it match the claim?

A percentage without a trace is only an assertion. The chromatogram should show a dominant peak, a stable baseline, and the integration used to calculate purity. Shoulders or split peaks suggest closely related impurities. The stated gradient, column, and detection wavelength indicate how the method was set up; the same sample can yield noticeably different purity values under different conditions.

Does the observed mass match the theoretical mass?

The report should state both the expected and the observed molecular weight, and the two should agree within normal instrument tolerance. Multiply charged ions in ESI spectra can make raw data look complicated, but the deconvoluted mass should still correspond to the calculated value. A researcher who knows the compound’s molecular formula can verify this independently; for a well-characterised molecule such as BPC-157, the expected mass is available from the literature and the peptide’s known sequence.

Is the data linked to the lot in hand?

Synthesis is a batch process, and impurity profiles differ between lots. Analytical data are only meaningful if the lot number on the report matches the lot number on the vial. Our companion article on reading a peptide certificate of analysis walks through the remaining fields of a typical report, and batch documentation is published on the Lab Results page.

Common Sources of Misleading Purity Claims

Several recurring issues explain why the same nominal purity can mean different things. Purity thresholds are sometimes quoted as ranges or minimums (for example, “95% or greater”) without stating the measured value. Different UV wavelengths, gradients, or integration settings produce different area percentages from an identical sample. A report may present an HPLC trace from a reference standard or a different lot. And a figure may be quoted with no accompanying mass spectrum, leaving identity unconfirmed. None of these is necessarily evidence of bad faith, but each is a reason to request the underlying data before relying on a summary number.

It is also worth remembering what neither technique measures. Neither reports endotoxin or bioburden, which require dedicated assays; neither describes residual solvents or heavy metals; and neither speaks to the stability of the peptide once it is reconstituted. Those questions belong to other tests and to proper handling in the laboratory.

Practical Implications for Experimental Work

For a laboratory, the practical consequences are straightforward. Identity should be confirmed by mass before purity is discussed at all, since a highly pure sample of the wrong molecule is not useful. Purity should be interpreted as a relative chromatographic figure rather than as a statement about vial contents. Where accurate molar concentrations are required, net peptide content, or at least a documented estimate of water and counterion content, should be taken into account when calculating stock solutions. And whenever a result seems inconsistent across batches, comparing the underlying chromatograms and spectra is usually more informative than comparing headline percentages.

In short, HPLC and mass spectrometry are best understood as two lenses on the same sample. One measures homogeneity and the other measures identity, and only together do they support the conclusion that a given lot contains what it is supposed to contain, in the proportion it is claimed to.

Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.